Literature DB >> 11914211

Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.

P J Pisella1, P Pouliquen, C Baudouin.   

Abstract

AIM: To determine the incidence of ocular toxicity of preservatives with glaucoma medications.
METHODS: A prospective epidemiological survey was carried out in 1999 by 249 ophthalmologists on 4107 patients. Ocular symptoms, conjunctiva, cornea, and eyelids were assessed. A chi(2) test was used for differences between preserved eye drops (P) and preservative free eye drops (PF).
RESULTS: 84% patients used P, 13% received PF, and 3% a combination of P and PF eye drops. All symptoms were more prevalent with P than with PF drops (p<0.001): discomfort upon instillation (43% versus 17%), and symptoms between instillations such as burning-stinging (40% versus 22%), foreign body sensation (31% versus 14%), dry eye sensation (23% versus 14%), tearing (21% versus 14%), and eyelid itching (18% versus 10%). An increased incidence (>2 times) of ocular signs was seen with P eye drops. The prevalence of signs and symptoms was dose dependent, increasing with the number of P drops. A reduction in the symptoms and signs was observed when patients changed from P to PF eye drops (p<0.001).
CONCLUSIONS: Symptoms and signs are less prevalent when PF drops are used. Moreover, most of the adverse reactions induced by P glaucoma medication are reversible after removing preservatives.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914211      PMCID: PMC1771067          DOI: 10.1136/bjo.86.4.418

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  47 in total

1.  Which patients are treated for glaucoma? An observational analysis.

Authors:  R L Bohn; J H Gurwitz; S M Yeomans; R J Glynn; L R Pasquale; A M Walker; J Avorn
Journal:  J Glaucoma       Date:  2000-02       Impact factor: 2.503

2.  Expression of CD40 and CD40 ligand in the human conjunctival epithelium.

Authors:  T Bourcier; M De Saint-Jean; F Brignole; A Goguel; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-01       Impact factor: 4.799

Review 3.  Adverse external ocular effects of topical ophthalmic medications.

Authors:  F M Wilson
Journal:  Surv Ophthalmol       Date:  1979 Sep-Oct       Impact factor: 6.048

4.  Incidence of ocular side effects of topical beta blockers in the Netherlands.

Authors:  L M van Beek; R J de Keizer; B C Polak; P R Elzenaar; N J van Haeringen; A Kijlstra
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

5.  Effects of ophthalmic vehicles on the stability of the precorneal film.

Authors:  M S Norn; A Opauszki
Journal:  Acta Ophthalmol (Copenh)       Date:  1977-02

6.  Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man.

Authors:  W S Wilson; A J Duncan; J L Jay
Journal:  Br J Ophthalmol       Date:  1975-11       Impact factor: 4.638

7.  Expression of Fas-Fas ligand antigens and apoptotic marker APO2.7 by the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory ocular surface disorders.

Authors:  F Brignole; M De Saint-Jean; M Goldschild; F Becquet; A Goguel; C Baudouin
Journal:  Exp Eye Res       Date:  1998-12       Impact factor: 3.467

8.  Quantitative cytotoxicity of preservatives evaluated in cell culture with Chang's human conjunctival cells--effect of temperature on cytotoxicity.

Authors:  N Takahashi
Journal:  Jpn J Ophthalmol       Date:  1982       Impact factor: 2.447

9.  Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas.

Authors:  N L Burstein
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-03       Impact factor: 4.799

Review 10.  Corneal cytotoxicity of topically applied drugs, vehicles and preservatives.

Authors:  N L Burstein
Journal:  Surv Ophthalmol       Date:  1980 Jul-Aug       Impact factor: 6.048

View more
  163 in total

1.  Bioavailability of fluorescein from a new drug delivery system in human eyes.

Authors:  A Steinfeld; A Lux; S Maier; R Süverkrüp; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

2.  Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.

Authors:  Arthur Shedden; Ingrid A Adamsons; Albert J Getson; Jean K Laurence; Christopher R Lines; David J Hewitt; Tony W Ho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

3.  [Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].

Authors:  S Pfennigsdorf; P Eschstruth
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

Review 4.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

5.  Conjunctival markers as predictable markers for preoperative glaucoma assessment.

Authors:  P-J Pisella
Journal:  Br J Ophthalmol       Date:  2006-11       Impact factor: 4.638

6.  Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.

Authors:  D L Easty; G Nemeth-Wasmer; J-P Vounatsos; B Girard; N Besnainou; P Pouliquen; L Delval; J-F Rouland
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

7.  Associated morbidity of nasolacrimal duct obstruction--a large community based case-control study.

Authors:  Arie Y Nemet; Shlomo Vinker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-22       Impact factor: 3.117

8.  Meibomian gland loss due to trabeculectomy.

Authors:  Hideto Sagara; Tetsuju Sekiryu; Hiroki Noji; Masashi Ogasawara; Yukinori Sugano; Hiroko Horikiri
Journal:  Jpn J Ophthalmol       Date:  2014-05-24       Impact factor: 2.447

9.  Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%.

Authors:  Quang H Nguyen; Matthew G McMenemy; Tony Realini; Jess T Whitson; Stephen M Goode
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

10.  A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients.

Authors:  Gianluca Manni; Marco Centofanti; Mariacristina Parravano; Francesco Oddone; Massimo G Bucci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.